Current filters:


8701 to 8710 of 97199 results

Canadian patients wait two and a half years for new drug access


As a result of government bureaucracies to approve new prescription drugs for public use, Canadians are…

North AmericaPharmaceuticalPoliticsPricingRegulation

Antidepressants continue to dominate OCD drug market


Treatment options for obsessive compulsive disorder (OCD) are currently dominated by antidepressants,…

Markets & MarketingNeurologicalPharmaceutical

Investor Icahn slams Amylin for not revealing B-MS bid


Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Watson confirms Lumigan and Latisse patent challenges; favorable Sanctura ruling


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

AllerganGenericsGenito-urinaryLatisseLegalLumiganOphthalmicsPatentsSanctura XRWatson Pharmaceuticals

Array BioPharma presents encouraging Ph II selumetinib results in ovarian cancer


Encouraging Phase II trial with selumetinib, a small-molecule MEK inhibitor developed by USA-based Array…

Array BioPharmaAstraZenecaOncologyPharmaceuticalResearchselumetinib

Head of NAFDAC advocates 200 billion naira lifeline for Nigerian pharma firms


The Director-General of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC),…

FinancialGenericsPharmaceuticalRest of the World

Adding cetuximab following colon cancer surgery does not improve disease-free survival


Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

EMA tightens conflicts-of-interests policies with immediate effect


The European Medicines Agency yesterday published its updated policy on conflicts of interests of the…


8701 to 8710 of 97199 results

Back to top